Please use this identifier to cite or link to this item:
https://essuir.sumdu.edu.ua/handle/123456789/81869
Or use following links to share this resource in social networks:
Tweet
Recommend this item
Title | Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study |
Authors |
Ferris, R.L.
Haddad, R. Even, C. Tahara, M. Dvorkin, M. Ciuleanu, T.E. Clement, P.M. Mesia, R. Kutukova, S. Zholudeva, L. Daste, A. Caballero-Daroqui, J. Keam, B. Vynnychenko, Ihor Oleksandrovych Lafond, C. Shetty, J. Mann, H. Fan, J. Wildsmith, S. Morsli, N. Fayette, J. Licitra, L. |
ORCID |
http://orcid.org/0000-0002-2339-6509 |
Keywords |
durvalumab head and neck squamous cell carcinoma immunotherapy metastatic randomized clinical trial tremelimumab |
Type | Article |
Date of Issue | 2020 |
URI | https://essuir.sumdu.edu.ua/handle/123456789/81869 |
Publisher | Elsevier |
License | Creative Commons Attribution - NonCommercial 4.0 International |
Citation | Durvalumab with or without tremelimumab in patients with recurrent ormetastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study / R.L. Ferris, R. Haddad, C. Even et al. // Annals of Oncology. — 2020. — Volume 31, Issue 7. — P. 942-950. — https://doi.org/10.1016/j.annonc.2020.04.001 |
Abstract |
Head and neck squamous cell carcinoma (HNSCC) is
among the 10 most common cancers worldwide, with
increasing incidence.1 Approximately 10% of patients with
HNSCC will be diagnosed with metastatic disease, and
even when treated early, around half will have disease
recurrence.2,3 The platinum-based doublet chemotherapy
with cetuximab regimen has been the most widely-used
therapy and considered standard of care (SoC) since it
was proven effective in 2007 for recurrent/metastatic
(R/M) HNSCC in the first-line setting.3,4 However, patients
typically progress even after aggressive first-line therapy,
and, until recently, the available options (e.g. cetuximab,
methotrexate, and taxanes) have delivered limited survival
benefits.3
Durvalumab is an immunotherapeutic agent that blocks
the interaction between programmed cell death ligand 1
(PD-L1) and its receptors.5 Durvalumab demonstrated
encouraging response rates and duration of response (DoR)
with a manageable safety profile in patients with HNSCC.6
Although monotherapy agents that block the programmed
cell death protein 1 (PD-1)/PD-L1 axis have shown clinical
activity, immunotherapy combinations have the potential
to improve upon monotherapy activity.7e9 Cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) and PD-L1/PD-1
pathways have largely non-redundant roles, suggesting
that blockade of both could have additive or synergistic
effects.10 Indeed, the combination of durvalumab and
tremelimumab, an anti-CTLA-4 monoclonal antibody, was
explored based on improved efficacy over monotherapy in
other solid tumor types.7 This observation, in addition to
the activity demonstrated by durvalumab in earlier R/M
HNSCC studies, served as the rationale to evaluate durvalumab
and tremelimumab in patients with R/M HNSCC.
Several studies, including the EAGLE study, were initiated to
evaluate combination immunotherapy regimens in various
patient groups.11,12 The EAGLE study was the first phase III
study to investigate durvalumab and tremelimumab in patients
with R/M HNSCC who had progressed after platinumbased
therapy.
During the conduct of the EAGLE study, anti-PD-1
monoclonal antibodies were approved for use for R/M
HNSCC progression following a platinum-based regimen.
Treatment with these immunotherapies resulted in a median
overall survival (OS) of 7.5e8.4 months.13,14 These
immunotherapies are now recommended for second-line
treatment as monotherapies for patients with R/M
HNSCC.3,13,14 More recently, immunotherapy alone or in
combination with platinum-based chemotherapy has
shown improvements in OS in the first-line setting,
underscoring the clinical utility of immunotherapy in
HNSCC.15
Here, we report the results of the randomized phase III
EAGLE trial evaluating durvalumab and durvalumab plus
tremelimumab versus SoC therapies in patients with R/M
HNSCC who have progressed following a platinumcontaining
regimen. |
Appears in Collections: |
Наукові видання (НН МІ) |
Views
Australia
1
China
15031464
Germany
1
Greece
1
Indonesia
1
Ireland
2733
Lithuania
1
Singapore
1
Sweden
1
Ukraine
2850328
United Kingdom
480136
United States
48280810
Vietnam
162
Downloads
Canada
1
China
324045
Germany
528
Ireland
324043
Lithuania
1
Singapore
29915975
South Africa
1
Ukraine
2850327
United Kingdom
1
United States
29915973
Vietnam
1
Files
File | Size | Format | Downloads |
---|---|---|---|
Vynnychenko_Durvalumab.pdf | 395.34 kB | Adobe PDF | 63330896 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.